Van ECK Associates Corp Sells 2,109 Shares of IDEXX Laboratories, Inc. $IDXX

Van ECK Associates Corp lessened its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 7.9% during the 2nd quarter, HoldingsChannel reports. The institutional investor owned 24,601 shares of the company’s stock after selling 2,109 shares during the quarter. Van ECK Associates Corp’s holdings in IDEXX Laboratories were worth $12,951,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Elyxium Wealth LLC purchased a new stake in IDEXX Laboratories in the 4th quarter valued at about $3,666,459,000. State Street Corp increased its position in shares of IDEXX Laboratories by 4.0% during the fourth quarter. State Street Corp now owns 3,656,626 shares of the company’s stock worth $2,473,817,000 after acquiring an additional 138,956 shares during the period. J. Stern & Co. LLP raised its stake in shares of IDEXX Laboratories by 23,694.7% during the fourth quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company’s stock valued at $1,795,072,000 after acquiring an additional 2,642,200 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of IDEXX Laboratories by 3.5% during the fourth quarter. Geode Capital Management LLC now owns 2,583,939 shares of the company’s stock valued at $1,749,380,000 after acquiring an additional 86,263 shares in the last quarter. Finally, Invesco Ltd. boosted its holdings in shares of IDEXX Laboratories by 13.8% in the fourth quarter. Invesco Ltd. now owns 1,502,218 shares of the company’s stock valued at $1,016,296,000 after purchasing an additional 181,955 shares during the period. Institutional investors own 87.84% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on IDXX. UBS Group increased their price objective on IDEXX Laboratories from $620.00 to $670.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 5th. Citigroup lifted their target price on IDEXX Laboratories from $650.00 to $670.00 and gave the company a “neutral” rating in a research report on Wednesday, August 5th. Wall Street Zen cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Sunday, July 12th. Barclays dropped their price target on IDEXX Laboratories from $800.00 to $710.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 11th. Finally, Weiss Ratings downgraded IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a report on Thursday. Six equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $747.00.

IDEXX Laboratories Price Performance

NASDAQ IDXX opened at $556.69 on Tuesday. The company has a market cap of $43.86 billion, a PE ratio of 39.15, a P/E/G ratio of 2.96 and a beta of 1.54. The firm’s 50 day moving average price is $559.23 and its 200-day moving average price is $572.70. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.87 and a current ratio of 1.17. IDEXX Laboratories, Inc. has a 52-week low of $518.55 and a 52-week high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Tuesday, August 4th. The company reported $4.27 EPS for the quarter, topping analysts’ consensus estimates of $3.94 by $0.33. The company had revenue of $1.22 billion during the quarter, compared to the consensus estimate of $1.20 billion. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. IDEXX Laboratories’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.50 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Sell-side analysts forecast that IDEXX Laboratories, Inc. will post 14.81 EPS for the current fiscal year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.